-
Je něco špatně v tomto záznamu ?
The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12
Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS9812
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 1997-01-01 do 2017-12-31
- MeSH
- amantadin analogy a deriváty farmakologie MeSH
- apoptóza účinky léků MeSH
- buněčný cyklus účinky léků MeSH
- cisplatina farmakologie MeSH
- geny p53 MeSH
- inhibitor p21 cyklin-dependentní kinasy metabolismus MeSH
- lidé MeSH
- mutace MeSH
- nádorové buněčné linie MeSH
- nádorový supresorový protein p53 genetika metabolismus MeSH
- organoplatinové sloučeniny farmakologie MeSH
- proteiny regulující apoptózu metabolismus MeSH
- protinádorové látky farmakologie MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.
Department of Laoratory Medicine Masaryk Memorial Cancer Institute Brno Czech Republic
Research and Development PLIVA Lachema a s Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026045
- 003
- CZ-PrNML
- 005
- 20150105154902.0
- 007
- ta
- 008
- 120817s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10637-009-9270-4 $2 doi
- 035 __
- $a (PubMed)19499188
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Roubalová, Eva $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Biology and Wildlife Diseases, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
- 245 14
- $a The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12 / $c Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek
- 520 9_
- $a In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.
- 650 _2
- $a amantadin $x analogy a deriváty $x farmakologie $7 D000547
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a proteiny regulující apoptózu $x metabolismus $7 D051017
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cisplatina $x farmakologie $7 D002945
- 650 _2
- $a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a geny p53 $7 D016158
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a organoplatinové sloučeniny $x farmakologie $7 D009944
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kvardová, Veronika $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Hrstka, Roman $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Bořilová, Šárka $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Michalová, Eva $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Dubská, Lenka $u Department of Laoratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Müller, Petr $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Sova, Petr $u Research and Development, PLIVA-Lachema a.s., Brno, Czech Republic
- 700 1_
- $a Vojtěšek, Bořivoj $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 773 0_
- $w MED00008129 $t Investigational new drugs $x 1573-0646 $g Roč. 28, č. 4 (2010), s. 445-453
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/19499188 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20150105155038 $b ABA008
- 999 __
- $a ok $b bmc $g 948087 $s 783391
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 28 $c 4 $d 445-453 $i 1573-0646 $m Investigational new drugs $n Invest New Drugs $x MED00008129
- GRA __
- $a NS9812 $p MZ0
- LZP __
- $a Pubmed-20120817/10/03